首頁 > 市場調查報告書 > 醫療設備

手術用器具

市場調查報告書

商品編碼

1439891

全球生物外科市場：洞察、競爭格局、市場預測：2030 年

Biosurgery - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

預計 2024 年至 2030 年期間，全球生物外科市場規模將以 9.23% 的複合年增長率擴大。生物外科市場受到心血管疾病盛行率上升、整形手術需求增加、前列腺癌等癌症發病率上升以及生物外科產品快速上市等多種因素的推動，正在推動正成長。

隨著心血管疾病的增加，生物外科的需求也增加。例如，根據英國心臟基金會2023年公佈的最新數據，2019年，亞洲有32,376,834人被診斷出患有心血管疾病，12,543,833人被診斷出患有冠狀動脈疾病，8,111,044人被診斷出患有中風。因此，生物外科產品安全有效，可在心血管手術中用於預防出血並促進術後傷口癒合。

此外，推動生物外科市場成長的另一個重要因素是整形外科需求的不斷成長。例如，根據2020年最新發布的整形外科統計報告，在美國進行的1560萬例整容手術中，有230萬例為整容手術，而1320萬例為微創手術。根據上述資料來源，2020年有680萬例重建手術（較2019年增加3%）。因此，整形外科需求的增加可以帶動生物外科的需求，從而為整個市場提供成長環境。

本報告考察了全球生物外科市場，並提供了市場概述，包括按產品類型、應用、最終用戶、地區和進入市場的公司概況劃分的趨勢。

BD
Baxter
SAMYANG HOLDING CORPORATION
B. Braun Melsungen AG
Stryker
Integra LifeSciences
Hemostasis LLC
Biom'Up
Pfizer Inc
Ethicon US LLC (Johnson & Johnson Services Inc)
CryoLife Inc
Zimmer Biomet
Kuros Biosciences
Orthofix US LLC
Tissue Regenix
Betatech Medical
Meril Life Sciences Pvt. Ltd
RTI Surgical
AROA BIOSURGERY LIMITED
BioCer Entwicklungs-GmbH

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

簡介目錄圖表

Product Code: DIMDCL0568

Biosurgery Market By Product Type (Sealant, Haemostat, Bone Graft Substitute, Adhesion Barriers, And Others), By Application (Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, And Others), By End-User (Hospitals And Ambulatory Surgical Centers), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing demand of plastic surgery and increasing incidence of cardiovascular diseases

The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2024-2030. The biosurgery market is witnessing a positive growth owing to various factors such as the increasing incidence of cardiovascular diseases, increasing demand of plastic surgery, the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market. Therefore, the market for biosurgery is estimated to grow during the forecast period from 2024 to 2030.

Biosurgery Market Dynamics:

As with the increasing incidence of cardiovascular diseases, the demand for biosurgery also increases. For instance, according to the latest data published by the British Heart Foundation in the year 2023, in 2019, in Asia, 32,376,834 people were affected with cardiovascular diseases, 12,543,833 individuals were diagnosed with coronary artery disease, and 8,111,044 population was detected with stroke. Thus, biosurgery products are used during the cardiovascular surgery, as they are safe, effective, prevent bleeding and initiate wound healing after the surgery. Therefore, the increasing incidence of cardiovascular diseases, can boost the demand of biosurgery, which could drive the overall biosurgery market forward over the forecast period (2024-2030).

Moreover, another key factor which is responsible for the growth of biosurgery market is the increasing demand of plastic surgery. For instance, according to the latest plastic surgery statistics report published in the year 2020, in America, out of 15.6 million of cosmetic operations, 2.3 million were cosmetic surgical procedures whereas 13.2 million cosmetic were minimally-invasive procedures. According to the source mentioned above, in 2020, reconstructive procedures were 6.8 Million (3% increase from 2019). Thus, increasing demand of plastic surgery, could boost the demand for biosurgery which in turn can provide a conductive growth environment for the biosurgery overall market.

Therefore, due to the aforementioned factors, biosurgery demand increases, which will surge the growth of the overall biosurgery market during the forecast period from 2024 to 2030.

However, rising cost of surgical procedures and complications related to surgical procedures such as infection, pain and others, this can hamper the global biosurgery market growth.

Additionally, the ongoing COVID-19 pandemic has significantly impacted the biosurgery market. There was a nationwide lockdown in almost every country, movement restrictions declined the number of hospital visits for elective surgeries and unavailability of the workforce at the production sites hampered the manufacturing rate of biosurgery products. However, due to spread of infection in the lungs by covid virus, it increased the demand of lung surgeries. Meanwhile, other elective surgeries were not given priority because COVID-19 patients were preferred more in terms of treatment. Moreover, according to the American Hospital Association 2020, between March and June 2020, hospitals in the United States lost an estimated USD 50.7 billion due to a decrease in "elective" treatments. According to the same research, these processes accounted for around 31% of net revenue in the United States on an average. However, with the masses being vaccinated, relaxation in the lockdown restrictions & the hospital visits of patients for elective surgeries as well as resumption of supply chains, logistics, and manufacturing units, the biosurgery can be expected to further grow during the forecast period.

Biosurgery Market Segment Analysis:

Biosurgery Market by Product Type (Sealant, Hemostat, Bone Graft Substitute, Adhesion Barriers, and Others), Application (Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery and Others), End-User (Hospitals and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the by-product type segment of the biosurgery market, hemostat is expected to hold a significant revenue share in the year 2023. The key attributes driving the growth of the biosurgery market includes, hemostats are developed to clamp small blood vessels for hemorrhage control, it is used to grasp & secure superficial fascia during undermining and debriding wounds. Moreover, this instrument is an excellent tool for exposing, exploring, and visualizing the deeper areas of a wound, hemostatic agent helps in the propagation of a more stable clot that is less prone to rupture during the moment of the casualty.

Furthermore, the key benefits associated with hemostats can increase the demand for biosurgery, which could drive the growth of the overall global biosurgery market during the forecast period. However, technological advancement and commercialization of biosurgery products also drives the market growth.

In July 2022, Medcura Inc, a medical device company, in partnership with ASO, LLC, a major U.S. manufacturer and supplier of first aid products, announced the launch of a high-performance, antibacterial hemostatic gel, Rapid-Seal®. It can be easily applied for irregular injuries where bandages could be inconvenient, as well as powders are messy & can cause discomfort.

In March 2020, Ethicon US LLC, a subsidiary of Johnson & Johnson Services Inc, announced the launch of SURGICEL® POWDER ABSORBABLE HEMOSTAT in Australia, New Zealand, as well as in Thailand. It is currently accessible in Singapore and Hong Kong. This development is a powdered adjunctive hemostat that aims to improve the effectiveness of disruptive bleeding control for surgeons.

Moreover, due to the interplay of the aforementioned factors, this can result in the rising demand for biosurgery, which in turn would provide a conducive growth environment for overall biosurgery market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall Biosurgery Market:

Among all the regions, North America is expected to dominate the global biosurgery market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. Factors such as the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market are expected to increase the demand for biosurgery in the North America market.

According to the latest data published by American Cancer Society, Inc. in the year 2023, it is estimated that in the year 2023, in United States, there will be 268,490 new cases of prostate cancer. Moreover, biosurgery products could be used to remove the prostate gland, as they are safe, effective, prevent bleeding and initiate wound healing after the surgery. Therefore, the increasing incidence of cancers such as prostate cancer, can boost the demand of biosurgery, which could drive the overall biosurgery market forward over the forecast period (2024-2030).

Furthermore, another factor that is responsible for the growth of biosurgery market is the surge in the biosurgery products launch in the market. For instance, in April 2022, Aroa Biosurgery, a soft tissue regeneration company, launched a new product named Myriad Morcells(TM), a morcellized (powder) format of Myriad Matrix(TM) which easily conforms to maximise interaction with uneven wound beds. Myriad Matrix(TM) is used during the surgical treatment of hidradenitis suppurativa, complex wounds and exposed vital structures.

In February 2020, Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, launched a large format version of its Endoform® Natural product in United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system. It is used to treat large surgical wounds with a single sheet of their extracellular matrix-based product.

Therefore, due to interplay of the factors mentioned above, there will be a higher demand for biosurgery, which would provide a conducive growth environment for the North American region in the biosurgery market.

Biosurgery Market Key Players:

Some of the key market players operating in the Biosurgery market include BD, Baxter, SAMYANG HOLDING CORPORATION, B. Braun Melsungen AG, Stryker, Integra LifeSciences, Hemostasis LLC, Biom'Up, Pfizer Inc, Ethicon US LLC (Johnson & Johnson Services Inc), CryoLife Inc, Zimmer Biomet, Kuros Biosciences, Orthofix US LLC, Tissue Regenix, Betatech Medical, Meril Life Sciences Pvt. Ltd, RTI Surgical, AROA BIOSURGERY LIMITED, BioCer Entwicklungs-GmbH, among others

Recent Developmental Activities in the Biosurgery:

In February 2022, Gunze Limited, announced that it has received medical device approval to manufacture and sell TENALEAF(TM), the first sheet-type absorbable adhesion barrier made in Japan. During open surgery and minimally invasive surgery, this device gives surgeons a new choice that can facilitate simple manipulation, provide a modest amount of adhesive strength for repositioning, and allow for conformable insertion.

In December 2022, BD, a global medical technology company, announced that it has acquired Tissuemed, Ltd., a privately held company which has headquarter in Leeds, England it is an industry leader in developing self-adhesive surgical sealant films. Tissuemed's lead product, Tissuepatch(TM), is a proprietary sealant technology that bonds to tissue to help control internal bleeding or stop leakage from surgical wounds.

In February 2022, Baxter International Inc, a leading global medical products company, announced acquisition of Seprafilm Adhesion Barrier which is used as an adjunct to limit the incidence, extent & severity of adhesions in certain pelvic and abdominal surgeries.

Key Takeaways from the Biosurgery Market Report Study:

Market size analysis for current biosurgery market (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the biosurgery market
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
Key companies dominating the global biosurgery market.
Various opportunities are available for the other competitor in the biosurgery market space.
What are the top-performing segments in 2023? How these segments will perform in 2030.
Which are the top-performing regions and countries in the current biosurgery market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for biosurgery market growth in the coming future?

Target Audience who can be benefited from this Biosurgery Market Report Study:

Biosurgery providers
Research organizations and consulting companies
Biosurgery-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in biosurgery
Various end-users who want to know more about the biosurgery market and latest technological developments in the biosurgery

Frequently Asked Questions for Biosurgery:

1. What is Biosurgery?

Biosurgery products are designed to reduce bleeding during various operations and to speed wound and surgical site healing. Due to their many benefits, including their efficacy, usability, and safety in various circumstances, these items are chosen in addition to conventional procedures (such as staples and sutures) for wound closure.

2. What is the market for Global Biosurgery?

The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2024-2030.

3. What are the drivers for the Global Biosurgery market?

The biosurgery market is witnessing a positive market growth owing to the factors such as the increasing incidence of cardiovascular diseases, increasing demand of plastic surgery, the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market.

4. Who are the key players operating in the Biosurgery market?

Some of the key market players operating in the biosurgery market include BD, Baxter, SAMYANG HOLDING CORPORATION, B. Braun Melsungen AG, Stryker, Integra LifeSciences, Hemostasis LLC, Biom'Up, Pfizer Inc, Ethicon US LLC (Johnson & Johnson Services Inc), CryoLife Inc, Zimmer Biomet, Kuros Biosciences, Orthofix US LLC, Tissue Regenix, Betatech Medical, Meril Life Sciences Pvt. Ltd, RTI Surgical, AROA BIOSURGERY LIMITED, BioCer Entwicklungs-GmbH.

5. Which region has the highest share in Biosurgery Market?

North America is expected to dominate the global biosurgery market. Factors contributing to the growth of biosurgery market in the North America region are the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market.

1.Biosurgery Market Report Introduction

2.Biosurgery Market Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking

3. Regulatory Analysis

3.1. The US
3.2. Europe
3.3. Japan
3.4. China

4. Biosurgery Market Key Factors Analysis

4.1. Biosurgery Market Drivers
- 4.1.1. The Increasing Incidence of Cardiovascular Diseases
- 4.1.2. Increasing Demand of Plastic Surgery
- 4.1.3. The Increasing Incidence of Cancers such as Prostate Cancer
- 4.1.4. Surge in the Biosurgery Products Launch in the Market
4.2. Biosurgery Market Restraints And Challenges
- 4.2.1. Rising Cost of Surgical Procedures
- 4.2.2. Complications Related to Surgical Procedures such as Infection, Pain and Others
4.3. Biosurgery Market Opportunities
- 4.3.1. Increasing Research and Development Activities in Biosurgery
- 4.3.2. Rising Healthcare Awareness

5. Biosurgery Market Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Biosurgery Market

7. Biosurgery Market Layout

7.1. By Product Type
- 7.1.1. Sealant
- 7.1.2. Hemostat
- 7.1.3. Bone Graft Substitute
- 7.1.4. Adhesion Barriers
- 7.1.5. Others
7.2. By Application
- 7.2.1. Cardiovascular Surgery
- 7.2.2. General Surgery
- 7.2.4. Plastic Surgery
- 7.2.4. Orthopedic Surgery
- 7.2.5. Others
7.3. By End User
- 7.3.1. Hospitals
- 7.3.2. Ambulatory Surgical Centers
7.4. By Geography
- 7.4.1. North America
  - 7.4.1.1. United States Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.1.2. Canada Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.1.3. Mexico Biosurgery Market Size in USD Million (2021-2030)
- 7.4.2. Europe
  - 7.4.2.1. France Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.2.2. Germany Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.2.3. United Kingdom Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.2.4. Italy Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.2.5. Spain Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.2.6. Russia Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.2.7. Rest of Europe Biosurgery Market Size in USD Million (2021-2030)
- 7.4.3. Asia-Pacific
  - 7.4.3.1. China Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.3.2. Japan Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.3.3. India Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.3.4. Australia Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.3.5. South Korea Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.3.6. Rest of Asia Pacific Biosurgery Market Size in USD Million (2021-2030)
- 7.4.4. Rest of the World (RoW)
  - 7.4.4.1. Middle East Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.4.2. Africa Biosurgery Market Size in USD Million (2021-2030)
  - 7.4.4.3. South America Biosurgery Market Size in USD Million (2021-2030)

8. Biosurgery Market Global Company Share Analysis - Key 3-5 Companies

9. Biosurgery Market Company and Product Profiles

9.1. BD
- 9.1.1. Company Overview
- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4. Product Listing
- 9.1.5. Entropy
9.2. Baxter
- 9.2.1. Company Overview
- 9.2.2. Company Snapshot
- 9.2.3. Financial Overview
- 9.2.4. Product Listing
- 9.2.5. Entropy
9.3. SAMYANG HOLDING CORPORATION
- 9.3.1. Company Overview
- 9.3.2. Company Snapshot
- 9.3.3. Financial Overview
- 9.3.4. Product Listing
- 9.3.5. Entropy
9.4. B. Braun Melsungen AG
- 9.4.1. Company Overview
- 9.4.2. Company Snapshot
- 9.4.3. Financial Overview
- 9.4.4. Product Listing
- 9.4.5. Entropy
9.5. Stryker
- 9.5.1. Company Overview
- 9.5.2. Company Snapshot
- 9.5.3. Financial Overview
- 9.5.4. Product Listing
- 9.5.5. Entropy
9.6. Integra LifeSciences
- 9.6.1. Company Overview
- 9.6.2. Company Snapshot
- 9.6.3. Financial Overview
- 9.6.4. Product Listing
- 9.6.5. Entropy
9.7. Hemostasis LLC
- 9.7.1. Company Overview
- 9.7.2. Company Snapshot
- 9.7.3. Financial Overview
- 9.7.4. Product Listing
- 9.7.5. Entropy
9.8. Biom'Up
- 9.8.1. Company Overview
- 9.8.2. Company Snapshot
- 9.8.3. Financial Overview
- 9.8.4. Product Listing
- 9.8.5. Entropy
9.9. Pfizer Inc
- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4. Product Listing
- 9.9.5. Entropy
9.10. Ethicon US LLC (Johnson & Johnson Services Inc)
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4. Product Listing
- 9.10.5. Entropy
9.11. CryoLife Inc
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4. Product Listing
- 9.11.5. Entropy
9.12. Zimmer Biomet
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4. Product Listing
- 9.12.5. Entropy
9.13. Kuros Biosciences
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4. Product Listing
- 9.13.5. Entropy
9.14. Orthofix US LLC
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4. Product Listing
- 9.14.5. Entropy
9.15. Tissue Regenix
- 9.15.1. Company Overview
- 9.15.2. Company Snapshot
- 9.15.3. Financial Overview
- 9.15.4. Product Listing
- 9.15.5. Entropy
9.16. Betatech Medical
- 9.16.1. Company Overview
- 9.16.2. Company Snapshot
- 9.16.3. Financial Overview
- 9.16.4. Product Listing
- 9.16.5. Entropy
9.17. Meril Life Sciences Pvt. Ltd
- 9.17.1. Company Overview
- 9.17.2. Company Snapshot
- 9.17.3. Financial Overview
- 9.17.4. Product Listing
- 9.17.5. Entropy
9.18. RTI Surgical
- 9.18.1. Company Overview
- 9.18.2. Company Snapshot
- 9.18.3. Financial Overview
- 9.18.4. Product Listing
- 9.18.5. Entropy
9.19. AROA BIOSURGERY LIMITED
- 9.19.1. Company Overview
- 9.19.2. Company Snapshot
- 9.19.3. Financial Overview
- 9.19.4. Product Listing
- 9.19.5. Entropy
9.20. BioCer Entwicklungs-GmbH
- 9.20.1. Company Overview
- 9.20.2. Company Snapshot
- 9.20.3. Financial Overview
- 9.20.4. Product Listing
- 9.20.5. Entropy